Agios Pharmaceuticals Inc
(STU:8AP)
€
42
2.6 (6.6%)
Market Cap: 2.40 Bil
Enterprise Value: 1.91 Bil
PE Ratio: 0
PB Ratio: 3.45
GF Score: 41/100 - Q1 2024 Agios Pharmaceuticals Inc Earnings Call TranscriptMay 02, 2024€31.4 (+3.29%)Earnings
- Q4 2023 Agios Pharmaceuticals Inc Earnings Call TranscriptFeb 15, 2024€24 (+3.45%)Earnings
- Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Agios Pharmaceuticals Inc ENERGIZE Phase 3 Topline Results TranscriptJan 03, 2024
- Q3 2023 Agios Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2023€19.8 (-1.00%)Earnings
- Agios Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Agios Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2023€23.6 (-0.84%)Earnings
- Agios Pharmaceuticals Inc to Review the Rise up Phase 2 Data and next Steps for the Phase 3 Portion of the Study Call TranscriptJun 26, 2023
- Agios Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 15, 2023
- Q1 2023 Agios Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2023€20.6 (+0.98%)Earnings
- Q4 2022 Agios Pharmaceuticals Inc Earnings Call TranscriptFeb 23, 2023€24.8Earnings
- Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Agios Pharmaceuticals Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 07, 2022
- Q3 2022 Agios Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2022€28.2 (+3.68%)Earnings
- Agios Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Agios Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2022€24.4 (+7.96%)Earnings
- Agios Pharmaceuticals Inc Leadership Update TranscriptJul 12, 2022
- Agios Pharmaceuticals Inc Investor Event (Virtual) TranscriptJun 13, 2022
- Q1 2022 Agios Pharmaceuticals Inc Earnings Call TranscriptMay 05, 2022€22.6 (+2.73%)Earnings
- Q4 2021 Agios Pharmaceuticals Inc Earnings Call TranscriptFeb 24, 2022€25.11 (-0.95%)Earnings
- Agios Pharmaceuticals Inc to Discuss the FDA Approval of PYRUKYND Call TranscriptFeb 18, 2022
- Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2022
- Agios Pharmaceuticals Inc to Host Investor Webcast TranscriptDec 14, 2021
- Agios Pharmaceuticals Inc Investor Day TranscriptNov 17, 2021
- Q3 2021 Agios Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2021€42.66 (+0.54%)Earnings
- Agios Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Agios Pharmaceuticals Inc Earnings Call TranscriptJul 29, 2021€42.19 (-1.47%)Earnings
- Agios Pharmaceuticals Inc to Present Mitapivat Clinical Data at EHA Virtual Congress TranscriptJun 11, 2021
- Q1 2021 Agios Pharmaceuticals Inc Earnings Call TranscriptApr 29, 2021€45.83 (+0.79%)Earnings
- Agios Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 17, 2021
- Agios Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 01, 2021
- Q4 2020 Agios Pharmaceuticals Inc Earnings Call TranscriptFeb 25, 2021€41.56 (-4.42%)Earnings
- Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Agios Pharmaceuticals Inc Investor Relations Event TranscriptDec 21, 2020
- Agios Pharmaceuticals Inc Virtual Investor Event to Review Data Presented at ASH TranscriptDec 08, 2020
- Agios Pharmaceuticals Inc at Piper Sandler Healthcare Conference (Virtual) TranscriptDec 02, 2020
- Agios Pharmaceuticals Inc Webinar on Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook TranscriptNov 19, 2020
- Q3 2020 Agios Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020€35.2 (-2.95%)Earnings
- Agios Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2020
- Agios Pharmaceuticals Inc at Canaccord Genuity Growth Conference (Virtual) TranscriptAug 13, 2020
- Q2 2020 Agios Pharmaceuticals Inc Earnings Call TranscriptJul 30, 2020€40.62 (-4.27%)Earnings
- Agios Pharmaceuticals Inc at BMO Capital Markets Prescription for Success Healthcare Conference (Virtual) TranscriptJun 23, 2020
- Agios Pharmaceuticals Inc Virtual Investor Webcast to Review Mitapivat Clinical Data Presented at EHA Annual Congress TranscriptJun 12, 2020
- Agios Pharmaceuticals Inc at RBC Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
- Q1 2020 Agios Pharmaceuticals Inc Earnings Call TranscriptApr 30, 2020€39.35 (-4.65%)Earnings
- Agios Pharmaceuticals Inc at Cowen HealthCare Conference TranscriptMar 03, 2020
- Agios Pharmaceuticals Inc at Leerink Global Healthcare Conference TranscriptFeb 25, 2020
- Q4 2019 Agios Pharmaceuticals Inc Earnings Call TranscriptFeb 13, 2020€44.62 (-0.18%)Earnings
- Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Agios Pharmaceuticals Inc Investor Event to Review Data Presented at ASH TranscriptDec 10, 2019
- Q3 2019 Agios Pharmaceuticals Inc Earnings Call TranscriptOct 31, 2019€26.73 (-4.12%)Earnings
- Agios Pharmaceuticals Inc Investor Event to Review AG-270 Phase 1 Data and Research TranscriptOct 27, 2019
- Agios Pharmaceuticals Inc to Discuss Data from ClarIDHy Study Presented at ESMO - Conference Call TranscriptSep 30, 2019
- Agios Pharmaceuticals Inc at Citi Biotech Conference TranscriptSep 05, 2019
- Q2 2019 Agios Pharmaceuticals Inc Earnings Call TranscriptAug 01, 2019€39.55 (-8.60%)Earnings
- Agios Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
- Q1 2019 Agios Pharmaceuticals Inc Earnings Call TranscriptMay 02, 2019€45.86 (-8.09%)Earnings
- Agios Pharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 11, 2019
- Agios Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference TranscriptFeb 28, 2019
- Q4 2018 Agios Pharmaceuticals Inc Earnings Call TranscriptFeb 14, 2019€48.46 (+0.04%)Earnings
Agios Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript
Feb 25, 2020 / 03:30PM GMT
Release Date Price:
€42.55
(-4.12%)
Andrew Scott Berens
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst
All right. Why don't we get started. I'm Andy Berens, Senior Biotech Analyst at SVB Leerink, and we're pleased to have Jackie Fouse, CEO of Agios with us.
Thank you for joining us, Jackie.
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director
Happy to be here.
Andrew Scott Berens
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst
Appreciate it. I know, obviously, it's a name that a lot of people know, but maybe there's some people in the room that don't know the story. What -- can we just get a brief overview of the company before we dive in?
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director
Sure. Sounds good. So I'm going to stand up for this. I just have like 3 or 4 slides to walk people through. For those of you who are less familiar with our story, these are the forward
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)